All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy


Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
You're logged in! Click here any time to manage your account or log out.
You're logged in! Click here any time to manage your account or log out.

The QuANTUM-First trial

Aug 8, 2022
Learning objective: After reading this article, learners will be able to cite a new clinical development in AML

Bookmark this article

During the EHA 2022 Congress, the AML Hub was pleased to speak with Hee-Je Kim, The Catholic University of Korea, Seoul, KR,  about the initial findings from the QuANTUM-First trial.

The QuANTUM-First study

Kim discusses the phase III study of quizartinib in combination with induction and consolidation chemotherapy, and as maintenance therapy, in patients with newly diagnosed FLT3-ITD AML. Kim outlines the study details, as well as results and comparisons of overall survival, complete remission rates, and study limitations.


Subscribe to get the best content related to AML delivered to your inbox